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Candida albicans is a common human-pathogenic fungal species with the ability to cause several dis-
eases including surface infections. Despite the clear difficulties of Candida control, antimicrobial peptides
(AMPs) have emerged as an alternative strategy for fungal control. In this report, different concentrations
of antifungal Cm-p1 (Cencritchis muricatus peptide 1) were electrospun into nanofibers for drug delivery.
The nanofibers were characterized by mass spectrometry confirming the presence of the peptide on the
scaffold. Atomic force microscopy and scanning electronic microscopy were used to measure the dia-
meters, showing that Cm-p1 affects fiber morphology as well as the diameter and scaffold thickness. The
Cm-p1 release behavior from the nanofibers demonstrated peptide release from 30 min to three days,
leading to effective yeast control in the first 24 hours. Moreover, the biocompatibility of the fibers were
evaluated through a MTS assay as well as ROS production by using a HUVEC model, showing that the
fibers do not affect cell viability and only nanofibers containing 10% Cm-p1–PVA improved ROS gene-
ration. In addition, the secretion of pro-inflammatory cytokines IL-6 and TNF-α by the HUVECs was also
slightly modified by the 10% Cm-p1–PVA nanofibers. In conclusion, the electrospinning technique applied
here allowed for the manufacture of biodegradable biomimetic nanofibrous extracellular membranes with
the ability to control fungal infection.
Introduction
Candida spp. are known to cause opportunistic infections in
immunocompromised patients.1,2 Candida albicans is con-
sidered the most common human-pathogenic fungal species,
causing several diseases including life-threatening blood-
stream and painful superficial infections.3,4 Moreover, invasive
candidiasis has been considered a significant cause of late-
onset infection in premature infants.5 Candidiasis is also
known as the major cause of mortality and morbidity in immu-
nocompromised patients as a result of AIDS, cancer chemo-
therapies or organ transplantation.4,6 Despite the advances in
treatment and management of fungal infections, there are
several reports about resistant fungal strains, treatment failure
and the scarcity of antifungal agents with low toxicity for
systemic C. albicans infections.6
Despite the clear difficulties of Candida control, antimicro-
bial peptides (AMPs) have emerged as alternative compounds
for pathogen control. These proteinaceous compounds show a
wide spectrum of activities against pathogenic bacteria, fungi,
viruses, parasites, as well as analgesic and immunomodulatory
activities.7–9 Cm-p1 (SRSELIVHQR) is an AMP isolated from
Cenchritis muricatus, a snail-like Caribbean sea mollusk,10 with
bactericidal activity against Staphylococcus aureus and Escheri-
chia coli. In complementary studies, Cm-p1 was chemically
synthesized, functionally characterized and further evaluated
regarding its antimicrobial activities, showing deleterious
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activities against yeasts and filamentous fungi. Moreover, no
toxicity against human red blood and RAW 264.7 cells was
noted.11
For AMPs to function properly, they must be delivered at an
appropriate dosage and time, which remains a significant
challenge. Several works report self-assembling peptides in
nanofibers for tissue engineering,12 drug release13 and bio-
material14 production. Moreover, the use of electrospun nano-
fibers has been investigated for potential wound dressings,
since the fibrous structure can protect wounds from microbial
contamination, making it possible to incorporate antimicro-
bial agents, growth factors and antiseptics.15,16 Antibiotics
incorporated in electrospun nanofibers include silver
compounds,17–20 vancomycin,21,22 gentamicin21–23 and rifam-
picin.24 However, some AMPs have also been employed in elec-
trospun nanofiber mats.13,25–30 Electrospinning is a promising
tool for peptide nanofiber production.31 This process allows
nanofiber fabrication of diverse materials with diameters
ranging from nanometers to micrometers, with high porosity,
a large surface area17,32 and efficient controlled drug release.31
Here, the electrospinning feasibility for a synthetic antimicro-
bial peptide, Cm-p1, in nanofibers of poly(vinyl alcohol) (PVA)
was explored in order to generate an antifungal wound dress-
ing with protective activity against Candida. Furthermore,
immunomodulatory activities, cellular viability and reactive
oxygen species generation with different scaffold formulations
were also determined. The scaffolds were further characterized
by scanning electron and atomic force microscopies as well as
by MALDI-TOF technology.
Results and discussion
Electrospun fiber mats of Cm-p1–PVA and peptide detection
Cm-p1–PVA-loaded nanofibrous membranes were fabricated by
electrospinning PVA. During the electrospinning process, para-
meters such as voltage and distance between the needle and
the collector were kept the same for every PVA and Cm-p1–PVA
fiber. Earlier, Cm-p1 was solubilized in deionized water under
stirring (200 rpm) and then 10% PVA was added to the peptide
solution. The hydrophilic nature of Cm-p1 allowed its solubili-
zation in deionized water. PVA, a synthetic polymer, has been
widely used to produce electrospun fiber mats33 attracting
attention due to its biocompatibility, hydrophilicity, physical
properties and chemical resistance.34,35 Furthermore, PVA
nanofibers have been applied in different fields, such as
enzyme immobilization, electrode materials, sensors and bio-
medical applications.36,37
Firstly, MALDI TOF analyses of fibers were performed in
order to identify the existence or absence of Cm-P1. Fig. 1a
demonstrates the free Cm-p1 molecular mass (1224.48 Da).
Moreover, an identical molecular mass was obtained by
directly ionizing the nanofiber containing Cm-p1–PVA
(Fig. 1b). The resulting observations reinforce the idea that the
peptide is encapsulated within the fiber through weak inter-
Fig. 1 MALDI TOF analysis of (a) free Cm-p1, (b) Cm-p1–PVA incorpor-
ated in an electrospun nanofiber and (c) the PVA nanofiber with no
peptide.
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actions. The PVA fiber, free of peptide, was also checked and
demonstrated the complete absence of Cm-p1 (Fig. 1c).
Microscopic characterization of fibers
To better evaluate the resulting fibers, SEM was performed
(Fig. 2a and b). The SEM micrographs in other magnifications
can be seen in Fig. 1 in the ESI.† The average diameters of the
spun fibers containing Cm-p1–PVA were 295.3 ± 44.9 nm, 293.5
± 45.8 nm, 210.6 ± 47.1 nm for concentrations of 2.5% Cm-p1-
PVA, 5% Cm-p1–PVA and 10% Cm-p1-PVA, respectively. Other-
wise, for the PVA fibers without Cm-p1, the average diameter
was 335.9 ± 28.2 nm. The nanofiber image characterizations in
Fig. 2a and b show that the fiber diameters decrease with the
presence of Cm-p1 when compared with the PVA fiber mat.
Furthermore, the standard deviation observed in the control
fibers was less than that in the fibers containing the peptide,
indicating that the PVA control fibers are more homogeneous
and bead-free in comparison to the fibers containing Cm-p1.
AFM was also used for further sample characterization
since this technique can be used to measure soft and fragile
adhesive surfaces, without harming the samples.38 Indeed, the
AFM images (Fig. 2c and d) confirmed the SEM results,
showing that the thickness of the nanofibers containing 10%
Cm-p1–PVA (1386 nm, Fig. 2b) was smaller than the PVA
(1535 nm, Fig. 2a) spun fibers. In complementary measure-
ments, the fiber diameters were also evaluated by AFM (Fig. 2c
and d). As in the SEM measurements, the 2.5% Cm-p1–PVA
(570.8 ± 81.6 nm) and 10% Cm-p1–PVA (550.2 ± 144.4 nm)
samples presented smaller diameters than the control samples
(990.9 ± 128.9 nm). However, by AFM, the diameter measure-
ments were higher than with SEM in every sample analyzed.
It is possible that during the SEM measurements the samples
were dehydrated, decreasing the diameters of the fibers, and/
or the diameters obtained by AFM are increased due to convo-
lution with the tip diameter. The differences between PVA and
Cm-p1–PVA fiber measurements were found to be significant
(** P < 0.0001) both in the SEM and AFM measurements.
Furthermore, the nanofibers were not uniform in the case of
the 10% Cm-p1–PVA sample, according to Fig. 2a and b. This
suggests that high concentrations of Cm-p1 may interfere with
the fiber morphology, due to the insufficient stretching of the
polymer jet during the electrospinning process through jet
suspension and needle obstruction, leading to bead formation
in the 10% Cm-p1–PVA mats. Nanofibers containing the anti-
microbial peptide nisin also displayed a smaller diameter
when compared with control fibers.27
Peptide nanofiber release
The peptide release from the Cm-p1–PVA nanofiber mats with
different Cm-p1 content is shown in Fig. 3. The behavior of
these nanofibers demonstrated peptide release from 30 min to
three days, leading to effective yeast control in the first 24 h.
Cm-p1 was rapidly released from the Cm-p1–PVA-loaded elec-
trospun nanofiber mats. Fig. 3a shows that after 120 min, Cm-
p1 was released into the dissolution medium from 2.5, 5 and
Fig. 2 SEM micrographs (a, b) and AFM images (c, d) of PVA and
Cm-p1–PVA fibers. (a) 10% PVA fibers with 1000× magnification, (b) 10%
Cm-p1–PVA fibers with 1000× magnification, (c) 10% PVA fibers and
(d) 10% Cm-p1–PVA fibers.
Fig. 3 Cm-p1–PVA release analyses from nanofibrous membranes (a)
using different scaffolds over 12 h and (b) from the same scaffolds for
72 h. NS: no significance. (*P < 0.1; **P < 0.01; ****P < 0.0001).
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10% Cm-p1–PVA nanofiber mats (Fig. 3a). In parallel, for
cumulative peptide release, another nanofiber fragment was
incubated in a glass tube at 37 °C. The buffer was changed
every 24 h until 3 days without removal, and the Cm-p1
amount was quantified. Fig. 3b shows that the release of the
Cm-p1–PVA spun fibers was higher during the first 24 h,
gradually decreasing after 48 and 72 h, probably due to a
reduction in the peptide concentration inside the fiber mat.
Fig. 2 in the ESI† presents the Cm-p1 quantification by using
HPLC chromatograms after 24 h of release; the quantified
nanofiber release at every time evaluated with the triplicate
media and standard deviation is shown in ESI Table 1.† Every
sample was quantified by HPLC and the chromatograms do
not show any alteration and modification in the spectrum,
suggesting that during the release assay the peptide was
stable. These values were also used to calculate the peptide
quantity for the antifungal assays. It is of interest that Cm-p1
release was sustained after 48 h, which could be a desirable
property for anti-infective biomaterials. The PVA nanofibers
could provide a fast-dissolving hydrophilic environment. The
fast release of Cm-p1–PVA from the nanofibers can be trig-
gered by an extremely high surface area and porosity of the
scaffolds. However, some studies suggest crosslinking PVA,
aiming to decrease the PVA hydrophilicity and then increase
the dissolution time of the PVA fibers.34,39,40 The synthetic
AMP fluorescein labelled inverse-Crabrolin (iCR-fluor) was
incorporated into electrospun poly(ε-caprolactone) and exhibi-
ted a 30% release rate in the first 30 min. After 2 h, the release
of the encapsulated molecule was 50%.25 The cumulative
release of plantaricin 423 from electrospun blends of poly(D,L-
lactide) and poly(ethylene oxide) was evaluated by Heunis and
colleagues26 and exhibited a high initial burst release and a
more continuous release of bacteriocin over an 8-day period.
Antifungal activity
The activity of the antifungal Cm-p1–PVA loaded nanofibers
against C. albicans was evaluated by a radial diffusion assay
(RDA) by comparing the inhibition halo between 30 mg mL−1
amphotericin B, free Cm-p1 and the PVA and Cm-p–PVA fiber
mats. The Cm-p1 concentrations were evaluated by HPLC from
the release quantification over 24 h and then used for the
bioassay. A quantitative list of antifungal activities of the
different loading agents and the ratio inhibition measure-
ments is presented in Table 1. In a previous assay, no halo was
visualized when the fibers were added directly to a Sabouraud
dextrose plate (data not shown). Only 10% Cm-p1–PVA nano-
fibers were able to inhibit C. albicans growth after the nano-
fibers had been solubilized in distilled water. Despite the
Cm-p1 activity, previous results11 presented higher activity
than 10% Cm-p1–PVA nanofibers. According to Hassounah
and co-workers,41 the establishment of hydrogen bonds
between the amino groups of the drugs and the alcohol groups
of PVA can lead to deactivation of the drugs due to the high
polarity of the alcoholic oxygen atom in PVA.41 In a preceding
theoretical structural analysis,11 it was predicted that Cm-p1
consists of a hydrophilic molecule scoring an impressive
average of hydropathicity and displays a minor central hydro-
phobic region bordered by basic amino acids at the
extremes.11 A three-dimensional theoretical model of Cm-p1
revealed an α-helix conformation with a distribution of net
charge caused by exposed cationic histidine (His8) and argi-
nine (Arg2 and Arg10) residues. Leucine (Leu5) and valine
(Val7), the hydrophobic preserved region, seem to perform a
critical role in the peptide’s antifungal activity, favoring
peptide-membrane interaction.11 Furthermore, the amino acid
residue, Val7, can be significant in fungal interaction. Studies
demonstrated that the pleurocidin lethal effects against
Candida albicans and other fungi occurs due to the presence of
an amidated valine residue at the C-terminus.42 This same
effect was also visualized with the antimicrobial peptide,
adenoregulin, against filamentous fungi and Gram-positive
and negative bacteria.43
Biocompatibility of Cm-p1–PVA fibers with mammalian cells
HUVEC viability (Fig. 4a) was evaluated in the presence of
different nanoscaffolds (the same peptide/polymer ratio was
used in the bioassay) using a MTS assay. None of the concen-
trations of the Cm-p1 scaffolds that were tested affected the
HUVEC viability when compared with the PVA scaffolds. These
results confirmed preliminary studies conducted by López-
Abarrategui and colleagues,11 where similar results were
observed using free Cm-p1 against RAW 264.7 murine macro-
phage-like cells. However, the proliferation of HUVECs was
affected in the presence of 10% Cm-p1–PVA scaffolds, as
shown in Fig. 4c. Meanwhile, for the PVA fibers, 2.5% Cm-p1–
PVA and 5% Cm-p1–PVA peptide concentrations did not
induce significantly lower cell attachment and proliferation in
primary endothelial cells.
Moreover, we also tried to better explore the mechanism of
action of the peptide fiber analyzed here. Since some anti-
microbial peptides act by inducing cell death through reactive
oxygen species (ROS) production, we evaluated the ROS pro-
duction by the HUVECs after 24 h (Fig. 4b). This analysis was
performed using the same proportions used for the activity
assay (2.5%, 5% and 10%). Only the 10% Cm-p1–PVA scaffolds
induced the formation of toxic ROS by the HUVECs (Fig. 4b).
Similar data has previously been obtained by using PvD, an
antifungal defensin peptide from the Phaseolus vulgaris seeds
Table 1 Quantitative list of nanofiber scaffolds with respect to concen-
tration and halo inhibition in Sabouraud dextrose agar measurements






Amphotericin B 30.00 14.10
Free Cm-p1 4.00 9.27
PVA fiber N/A N/D
2.5% Cm-p1– PVA fiber 1.92 N/D
5% Cm-p1– PVA fiber 3.04 N/D
10% Cm-p1– PVA fiber 5.26 3.94
aN/A: not applicable; N/D: not detectable.
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with activity against C. albicans. This peptide induces fungal
cell death by membrane permeabilization and the stimulation
of oxidative stress injury, with the generation of ROS and nitric
oxide.45,46 This same mechanism was also described for
another plant defensin, HsAFP1 from Heuchera sanguinea,44
which induces several pro-apoptotic signals including ROS
accumulation, leading to cell death. Unlike Cm-p1, both
HsAFP1 and PvD were able to induce fungal cell death by ROS
generation at low concentrations (5 µg mL−1 and 100 µg mL−1,
respectively). According to the data in Fig. 4b and bioassay
results, it is possible that the Cm-p1 mechanism of action may
involve ROS generation due to an improvement in production
(Fig. 4b). However, further studies are needed to confirm this
hyphothesis.
Furthermore, nanofiber hemolytic activity was evaluated
after 24 h of release (ESI, Fig. 3†). No concentrations (2.5%,
5% and 10%) of nanofibers induced hemoglobin leakage. In
the same way, in brief experiments, no concentrations of free
Cm-p1 were capable of causing hemolysis.11 Antifungal drugs
have several toxicity problems against mammalian cells. The
authors of a previous study affirmed that this outcome is prob-
ably due to the low hydrophobicity of Cm-p1.11
The secretion of pro-inflammatory cytokines, TNF-α
(Fig. 5a) and IL-6 (Fig. 5b), from RAW 264.7 macrophages after
24 h of exposure with the control scaffolds (no peptide) and
scaffolds carrying different concentrations of Cm-p1 was evalu-
ated. Only the 10% Cm-p1–PVA scaffold presented significant
Fig. 4 Biocompatibility of peptide/nanoscaffolds with mammalian cells.
Evaluation of (a) HUVEC viability; toxicity profiles of the control scaffold
(no peptide) and peptides with different concentrations in the HUVECs.
Relative viability was determined by using the MTS assay and all values
were normalized to the values obtained with the control group. (b) ROS
generation with different scaffold formulations was determined by a
ROS assay and represented as fold change compared to the control. (c)
Viable HUVECs (in green) in different nanoscaffold groups stained with
calcein AM dye, with less cell attachment and proliferation noted in the
10% group (white arrows) compared to the others. The data represent
the mean ± SD. NS: no significance. (*P < 0.1).
Fig. 5 Evaluation of cytokine pro-inflammatory secretion of TNF-α (a)
and IL-6 (b) by RAW 264.7 macrophages, after 24 h of exposure with the
control scaffolds (no peptide) and scaffolds carrying different percen-
tages of peptides, as obtained by ELISA analysis. LPS was used as a posi-
tive control. The data represent the mean ± SD. NS: no significance.
(*P < 0.1; ****P < 0.0001).
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cytokine generation when compared with the control scaffolds.
However, this production is 3 and 4 times lower for IL-6 and
TNF-α, respectively, in comparison to the LPS-stimulated
group. Moreover, the production of proinflammatory cyto-
kines, such as IL-6 and TNF-α, plays an important role, leading
to an inflammatory response by inducing other anti-inflamma-
tory mediators, the activation of T cells and the secretion of
antibodies by B cells.47
In this context, the capacity to induce the secretion of cyto-
kines to promote the recruitment of immune cells of cathelici-
dins is well known. The release of TNF-α and IL-6 was induced
by cathelicidin LL-37 in keratinocytes and immature dendritic
cells at much lower concentrations.48,49 Furthermore, the bac-
teriocin plataricin A, produced by Lactobacillus plantarum, was
also shown to increase migration and cell proliferation, as well
as stimulating the expression of vascular endothelial growth
factor A and IL-8 in keratinocytes.50 Kindrachuk et al.51
demonstrated that nisin Z presents immunomodulatory activi-
ties and modulates the host immune response similarly to
natural host defense peptides. Although Cm-p1 slightly
induces IL-6 and TNF-α secretion in mammalian cells in
higher concentrations, this peptide did not present detectable
cytotoxicity. In addition, TNF-α and IL-6 production was seen
after 24 h of cell culture incubation, where the peptide release,
shown in Fig. 3b, is 5.26 mg mL−1. However, after this period
the peptide release decreased greatly, reaching an insignificant
value after 72 h of cell culture incubation (Fig. 3b). The cyto-
kine production can be minimized, exposing the cells to nano-
fibers after 24 h, when the Cm-p1 concentration drops.
Nevertheless, it is important to emphasize that Cm-p1 activity
will also be minimized. In this way, the induction of low pro-
inflammatory cytokine production happens only in the early
period of its use, helping the microorganism’s elimination
and/or prevention. The low cytokine production favors the
opsonization of pathogens, the clearance of apoptotic cells
and the activation of complement.47,52
Conclusions
In this report we describe the production of nanofibers that
encapsulate antifungal peptides. At the moment, few anti-
microbial peptides have been incorporated into nanofibers53
and the use of the electrospinning tool should be explored
through the incorporation of antimicrobial peptides. In
summary, 10% Cm-p1–PVA concentration was able to decrease
the growth of C. albicans. Moreover, with this same concen-
tration, Cm-p1 slightly induced ROS generation without
affecting the cell viability, as well as being capable of causing
low induction of IL-6 and TNF-α production by mammalian
cells. Electrospun fibers generated here may be useful as
wound care and drug delivery systems. The emerging field of
intelligent nanomaterials for medical applications has gained
attention in recent decades. However, preclinical development




Polyvinyl alcohol (PVA) with a hydrolysis degree of 89% and a
molecular mass of 134 ± 4 kDa was obtained from Vetec,
Brazil. The Candida albicans ATCC 10231 strain was obtained
from the Universidade Católica Collection and was grown
on liquid RPMI medium (Sigma-Aldrich, USA). Mouse RAW
264.7 macrophage cells were purchased from the ATCC
(TIB-71) and cultured in DMEM medium supplemented with
10% FBS and 1% penicillin/streptomycin at 37 °C in 5% CO2.
Lipopolysaccharide (LPS) was obtained from InvivoGen.
HUVECs (primary human umbilical vein endothelial cells,
Lonza) were cultured in endothelial basal medium 2 (EGM-2
BulletKit, Lonza) supplemented with growth factors (hFGF-β,
hydrocortisone, VEGF, R3-IGF-1, ascorbic acid, heparin, FBS,
hEGF).
Peptide synthesis and purity degree evaluation
The peptide was purchased from enterprise Peptide 2.0 Incor-
porated,8 which synthesized the peptide with 95% purity. The
Cm-p1 molecular mass was confirmed by using MALDI-TOF
MS/MS analysis (Autoflex, Bruker Daltonics, Billerica, MA). The
purified peptide was solubilized in a minimum water volume
and blended with an α-cyano-4-hydroxycinnamic acid satu-
rated matrix solution (1 : 3, v : v), spotted onto a MALDI TOF
target plate and air-dried at room temperature for 10 min. The
α-cyano-4-hydroxycinnamic acid matrix solution was made at
50 mM in H2O–ACN–TFA (50 : 50 : 0.3, v : v : v). The peptide
monoisotopic mass was gained in the reflector mode with
external calibration, using the Peptide Calibration Standard II
(up to 4000 Da mass range, Bruker Daltonics, Billerica, MA).
The synthetic peptide concentrations were obtained by using
the measurements of absorbance at 205, 215 and 225 nm, as
defined by Murphy and Kies (1960).
Electrospun non-woven mats of PVA/peptide
Different concentrations of Cm-p1 (2.5%, 5% and 10%, w/v)
were solubilized in 0.5 ml of deionized water and stirred over-
night at 70° C. After 12 h, 50 mg of PVA were slowly added in
order to produce a 10% w/v solution and stirred at 70 °C until
complete solubility was achieved. The electrospinning process
was carried out on a horizontal configuration; a 1 mL plastic
syringe with a stainless steel capillary (BD, gauge 12) was
loaded with the PVA/polypeptide solution and processed at
15 kV supplied by a high voltage source (homemade), with a
flow of 0.2 mL h−1 using a syringe pump (NE-2000, New Era,
Pump Systems Inc.) and a working distance of 10 cm from the
needle tip to the collector. The produced mats were collected
on aluminum foils.
Scanning electron microscopy
For morphological analysis of the nanofibers by scanning elec-
tron microscopy (SEM), a Zeiss DSM 962 (Carl Zeiss, Germany)
microscope was used. The nanofiber samples of the cover
slip were affixed to the surface of stubs, using double-sided
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adhesive conductive carbon tape. Stubs were covered with an
ultra-thin gold layer (20 nm) using the Sputter Coat Emitech
K550. SEM images were analyzed and captured, and the dia-
meters of the fibers in the mats were determined using
10 000× magnification by the Image J Tool for Windows
version 3.0. Statistical analysis was performed using Microsoft
Excel’s one-way analysis of variance (ANOVA).
Atomic force microscopy measurements
Atomic force microscopy (AFM) images were obtained on a JPK
Instruments NanoWizard II (Berlin, Germany) mounted on a
Carl Zeiss Axiovert 200 inverted microscope (Jena, Germany).
Images were performed in an intermittent contact mode (air)
using ACL silicon cantilevers from AppNano (Huntingdon, UK)
with a tip radius of 6 nm, a resonant frequency of approxi-
mately 190 kHz and spring constant of 58 N m−1. All images
were obtained with similar AFM parameter (setpoint, scan rate
and gain) values. The scan rate was set between 0.3 and 0.6 Hz
and the setpoint was close to 0.3 V. Height and error signals
were collected and images were analyzed with the JPK image
processing software v. 4.2.53 (JPK Instruments).
Cm-p1–PVA nanofiber release analyses
The Cm-p1–PVA release characterization was made using an
in vitro elution method.21 Samples with an area of 2 cm ×
2 cm, cut from the electrospun membranes, were put into
glass test tubes (one sample per test tube, total number = 3)
with 1 mL of phosphate-buffered solution (0.15 mol L−1,
pH 7.4) in each. The glass test tubes were kept at 37 °C for
24 h, after which the eluent was removed and evaluated. Fresh
phosphate-buffered solution (1 mL) was added for the follow-
ing 24 h period, and the procedure was sustained for 15 days.
Drug concentrations in the eluents were analyzed using the
standard curve carried out in RP-HPLC. At the same time,
samples with the same area cut from the nanofibers were put
into glass test tubes (one sample per test tube, total number =
3) with 1 mL of phosphate-buffered solution (0.15 mol L−1,
pH 7.4) in each. The glass test tubes were kept at 37 °C for 0.5,
1, 1.5, 2, 4, 8, 12 and 24 h, after which the eluent was collected
and determined by the standard HPLC assay curve. For
peptide quantification, a standard curve was carried out with
several amounts (0.2, 0.4, 0.6, 0.8 and 1.0 mg) of peptide
weighed in an analytical balance (AND GH-202, USA). The
standard deviation for the sample weighed was 5% for each
application into the C18 analytical column in a linear gradient
of 5 to 95% of acetonitrile in 0.01% of trifluoroacetic acid
(TFA). The line equation observed, y = 1297x + 201 with R2
value of 0.996, was used to quantify the samples in all the
steps of the release measurements.
Antifungal bioassays
A bioassay against fungi was performed by measuring fungal
growth inhibition using a radial diffusion assay (RDA).25
Sabouraud dextrose plates were made by dissolving 10 g L−1
peptone, 20 g L−1 dextrose, and 4% agar in distilled water,
after which the solution was autoclaved. The test solutions
were prepared from samples with an area of 2 cm × 2 cm, cut
from the electrospun membranes, put into glass test tubes
containing 1 mL of autoclaved distilled water and then kept
for 24 h at 37 °C and 200 rpm. The samples were then lyophi-
lized and solubilized with autoclaved distilled water. When the
plates had hardened, circular holes were made in the medium
with the large end of a 2–200 μL pipette tip. Into these holes,
20 μL of the solutions to be tested were added. 10 mL of
Sabouraud dextrose medium containing 2 % of agarose was
then mixed with a suspension of 5 mL of fungi grown over-
night, after which it was poured into petri dishes yielding a
thickness of approximately 2 mm. The plates were then set to
incubate at 37 °C. Amphotericin B (30 µg ml−1) was used as
the positive control. The following day, the plates were
inspected for antimicrobial activity against the fungal strain.
The activity was recognized as a clear zone of inhibition
around the hole, and the larger the diameter of this ring, the
higher the activity of the loading agent against this strain, as
analysed by the Image J Tool for Windows version 3.0. Statisti-
cal analysis was performed using Microsoft Excel’s one-way
analysis of variance (ANOVA).
Nanoscaffold/peptide immune toxicity analysis toward
mammalian cells
Plasma treated nanoscaffold surfaces with different nanofiber
formulations (0.3 cm2) were inserted into each well of a 96-well
plate. Plasma surface chemical treatment using a plasma
reactor was done to improve the surface hydrophilicity and cell
adhesion properties of the polymeric nanoscaffolds. The
peptide/polymer ratios used in these experiments were 2.5%,
5% and 10%, the same ratios observed in the antimicrobial
analysis. Plasma treatment was used to improve the hydrophi-
licity of nanoscaffold surface. This procedure was followed by
addition of RAW 264.7 macrophages with 2 × 103 cells per well,
which were grown for 24 h. As positive control, RAW cells were
treated with 100 ng mL−1 of LPS. ELISA assays (SA Biosciences)
of the conditioned media from different groups were carried
out according to the manufacturer’s protocol to quantify the
secreted cytokines IL-6 and TNF-α by the RAW cells. Each
experiment was performed in triplicate.54–56
Cell viability assays
In a similar way, cell viability of the HUVECs in the presence
of different nanoscaffolds was measured using a Cell Titer 96
Aqueous Non-Radioactive Cell Proliferation MTS Assay
(Promega) according to the manufacturer’s protocol. To main-
tain the same standardization, the same peptide/polymer
ratios (2.5%, 5% and 10%) were used in this assay. For this,
2 × 104 HUVECs were grown on the different nanoscaffold
groups and the absorbance was measured using a plate reader
at 490 nm after 24 h of cell culture. Each experiment was
performed in triplicate.57
Superoxide production analyses
Intracellular production of superoxide by the HUVECs, due to
exposure to the peptide/nanoscaffolds, was evaluated using an
Paper Nanoscale















































intracellular ROS assay (Cell Biolabs, Inc) according to the
manufacturer’s instructions. Similar to the above-mentioned
experimental method, 2 × 104 HUVECs were grown on the
nanoscaffolds for 24 h and the fluorescence signals in each
well were quantified with a fluorometric plate reader at
480 nm/530 nm. The assay used a cell-permeable fluorogenic
probe, 2′,7′-dichlorodihydrofluorescein diacetate, to trace the
ROS. The fluorescence intensity in each well is directly pro-
portional to the ROS level within the cell cytosol.58 In a separ-
ate experiment, the cells grown on the scaffolds for 48 h were
stained with cell-permeant calcein AM dye (Life Technologies)
to trace viability.
Hemolytic activity
The hemolytic activity was determined according to Bignami
(1993)59 and Tramer (2012)60 with modifications. Earlier, 1 mL
of fresh blood from BALB/c mice was fractionated by centrifu-
gation and the red blood cells were recovered in 1% (v/v) PBS.
The suspension was washed three times with PBS and ali-
quoted in microtubes and in PVA and 2.5%, 5% and 10% Cm-
p1–PVA; after 24 h of release, the nanofibers were added and
set aside for 1 h. Saline solution and 0.1% Triton X-100 were
used as the negative and positive control, respectively. After
1 h, the microtubes were centrifuged (1000 g; 2 min) and the
supernatant was applied in the 96 well plate. The absorbance
was measured using a reader at 406 nm (Bio-Tek PowerWave
HT, EUA).
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